Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures

Saved in:
Bibliographic Details
Published in:Atención primaria 2000-09, Vol.26 (4), p.274-275
Main Authors: Hawkins Carranza, F, López Alvarez, M B
Format: Article
Language:Spanish
Subjects:
Alendronate - economics
Alendronate - therapeutic use
Controlled Clinical Trials as Topic
Cost-Benefit Analysis
Female
Hip Fractures - prevention & control
Humans
Middle Aged
Osteoporosis - drug therapy
Placebos
Postmenopause
Quality of Life
Randomized Controlled Trials as Topic
Risk Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 275
container_issue 4
container_start_page 274
container_title Atención primaria
container_volume 26
creator Hawkins Carranza, F
López Alvarez, M B
description
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72439581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72439581</sourcerecordid><originalsourceid>FETCH-LOGICAL-p540-54e5ed18b8637e7d736260393a5fb9da97f7a84e2ed8f9489d76b0e199d03c043</originalsourceid><addsrcrecordid>eNo10DtPwzAUBWAPIFoKfwF5YovkRxzHI6p4SZVYOiJFTnytGiV28HUq9d9TRJnO8p0znCuyZoKLqlGNXpFbxC_GhDBS35AV55wxZdiafG4TFgrew1DCESIgUhvteMKANHlqR4gup2gL0CNkXJDOox2gTzREWg5A5wznXgkp_vpDmKnPdihLBrwj196OCPeX3JD9y_N--1btPl7ft0-7alY1q1QNChxv-7aRGrTTshENk0Za5XvjrNFe27YGAa71pm6N003PgBvjmBxYLTfk8W92zul7ASzdFHCAcbQR0oKdFrU0quVn-HCBSz-B6-YcJptP3f8d8gfK7Vvf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72439581</pqid></control><display><type>article</type><title>Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures</title><source>Open Access: PubMed Central</source><creator>Hawkins Carranza, F ; López Alvarez, M B</creator><creatorcontrib>Hawkins Carranza, F ; López Alvarez, M B</creatorcontrib><identifier>ISSN: 0212-6567</identifier><identifier>PMID: 11100590</identifier><language>spa</language><publisher>Spain</publisher><subject>Alendronate - economics ; Alendronate - therapeutic use ; Controlled Clinical Trials as Topic ; Cost-Benefit Analysis ; Female ; Hip Fractures - prevention &amp; control ; Humans ; Middle Aged ; Osteoporosis - drug therapy ; Placebos ; Postmenopause ; Quality of Life ; Randomized Controlled Trials as Topic ; Risk Factors</subject><ispartof>Atención primaria, 2000-09, Vol.26 (4), p.274-275</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11100590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hawkins Carranza, F</creatorcontrib><creatorcontrib>López Alvarez, M B</creatorcontrib><title>Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures</title><title>Atención primaria</title><addtitle>Aten Primaria</addtitle><subject>Alendronate - economics</subject><subject>Alendronate - therapeutic use</subject><subject>Controlled Clinical Trials as Topic</subject><subject>Cost-Benefit Analysis</subject><subject>Female</subject><subject>Hip Fractures - prevention &amp; control</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Osteoporosis - drug therapy</subject><subject>Placebos</subject><subject>Postmenopause</subject><subject>Quality of Life</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Factors</subject><issn>0212-6567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNo10DtPwzAUBWAPIFoKfwF5YovkRxzHI6p4SZVYOiJFTnytGiV28HUq9d9TRJnO8p0znCuyZoKLqlGNXpFbxC_GhDBS35AV55wxZdiafG4TFgrew1DCESIgUhvteMKANHlqR4gup2gL0CNkXJDOox2gTzREWg5A5wznXgkp_vpDmKnPdihLBrwj196OCPeX3JD9y_N--1btPl7ft0-7alY1q1QNChxv-7aRGrTTshENk0Za5XvjrNFe27YGAa71pm6N003PgBvjmBxYLTfk8W92zul7ASzdFHCAcbQR0oKdFrU0quVn-HCBSz-B6-YcJptP3f8d8gfK7Vvf</recordid><startdate>20000915</startdate><enddate>20000915</enddate><creator>Hawkins Carranza, F</creator><creator>López Alvarez, M B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20000915</creationdate><title>Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures</title><author>Hawkins Carranza, F ; López Alvarez, M B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p540-54e5ed18b8637e7d736260393a5fb9da97f7a84e2ed8f9489d76b0e199d03c043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2000</creationdate><topic>Alendronate - economics</topic><topic>Alendronate - therapeutic use</topic><topic>Controlled Clinical Trials as Topic</topic><topic>Cost-Benefit Analysis</topic><topic>Female</topic><topic>Hip Fractures - prevention &amp; control</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Osteoporosis - drug therapy</topic><topic>Placebos</topic><topic>Postmenopause</topic><topic>Quality of Life</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hawkins Carranza, F</creatorcontrib><creatorcontrib>López Alvarez, M B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Atención primaria</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hawkins Carranza, F</au><au>López Alvarez, M B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures</atitle><jtitle>Atención primaria</jtitle><addtitle>Aten Primaria</addtitle><date>2000-09-15</date><risdate>2000</risdate><volume>26</volume><issue>4</issue><spage>274</spage><epage>275</epage><pages>274-275</pages><issn>0212-6567</issn><cop>Spain</cop><pmid>11100590</pmid><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0212-6567
ispartof Atención primaria, 2000-09, Vol.26 (4), p.274-275
issn 0212-6567
language spa
recordid cdi_proquest_miscellaneous_72439581
source Open Access: PubMed Central
subjects Alendronate - economics
Alendronate - therapeutic use
Controlled Clinical Trials as Topic
Cost-Benefit Analysis
Female
Hip Fractures - prevention & control
Humans
Middle Aged
Osteoporosis - drug therapy
Placebos
Postmenopause
Quality of Life
Randomized Controlled Trials as Topic
Risk Factors
title Cost effectiveness analysis of alendronate versus placebo in the prevention of hip fractures
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A37%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20effectiveness%20analysis%20of%20alendronate%20versus%20placebo%20in%20the%20prevention%20of%20hip%20fractures&rft.jtitle=Atenci%C3%B3n%20primaria&rft.au=Hawkins%20Carranza,%20F&rft.date=2000-09-15&rft.volume=26&rft.issue=4&rft.spage=274&rft.epage=275&rft.pages=274-275&rft.issn=0212-6567&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72439581%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p540-54e5ed18b8637e7d736260393a5fb9da97f7a84e2ed8f9489d76b0e199d03c043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72439581&rft_id=info:pmid/11100590&rfr_iscdi=true